Comment: Novo’s Catalent deal faces scrutiny over foreclosure concerns in UK, US obesity-drug market
Novo Holdings’ $16.5 billion planned acquisition of Catalent to strengthen its leading position in the anti-obesity drugs market is already facing calls for regulators to take a closer look, because by...To view the full article, register now.
Already a subscriber? Click here to view full article